SMTL ID : 7p77.1

SARS-CoV-2 spike protein in complex with sybody#15 and sybody#68 in a 3up conformation

Coordinates

PDB Format Compare

Method

ELECTRON MICROSCOPY

Oligo State

hetero-3-3-3-mer

Ligands

10 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)(Non-covalent)

NAG-NAG.1: 4 residues within 4Å: Chain A: N.1098, T.1100, H.1101, F.1103 No protein-ligand interaction detected (PLIP) NAG-NAG.3: 2 residues within 4Å: Chain A: N.801, S.803 No protein-ligand interaction detected (PLIP) NAG-NAG.4: 4 residues within 4Å: Chain A: N.331, P.579, Q.580, L.582 No protein-ligand interaction detected (PLIP) NAG-NAG.5: 1 residues within 4Å: Chain A: N.1134 No protein-ligand interaction detected (PLIP) NAG-NAG.6: 4 residues within 4Å: Chain B: T.716, N.717, L.922, Q.1071 No protein-ligand interaction detected (PLIP) NAG-NAG.7: 3 residues within 4Å: Chain B: N.801, S.803, Q.804 No protein-ligand interaction detected (PLIP) NAG-NAG.8: 1 residues within 4Å: Chain B: N.1134 No protein-ligand interaction detected (PLIP) NAG-NAG.9: 2 residues within 4Å: Chain B: N.331, Q.580 No protein-ligand interaction detected (PLIP) NAG-NAG.10: 1 residues within 4Å: Chain C: N.1134 No protein-ligand interaction detected (PLIP) NAG-NAG.14: 3 residues within 4Å: Chain B: N.1098, T.1100, H.1101 1 PLIP interactions: 1 interactions with chain B Hydrogen bonds: B:H.1101

4 x NAG- NAG- BMA: beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose

NAG-NAG-BMA.2: 4 residues within 4Å: Chain A: N.717, L.922, Q.926, Q.1071 No protein-ligand interaction detected (PLIP) NAG-NAG-BMA.12: 4 residues within 4Å: Chain C: N.717, L.922, Q.926, Q.1071 No protein-ligand interaction detected (PLIP) NAG-NAG-BMA.15: 3 residues within 4Å: Chain C: N.801, S.803, Q.804 No protein-ligand interaction detected (PLIP) NAG-NAG-BMA.16: 2 residues within 4Å: Chain C: N.331, Q.580 No protein-ligand interaction detected (PLIP)

1 x NAG- BMA: beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)

NAG-BMA.11: 3 residues within 4Å: Chain C: N.1098, T.1100, H.1101 2 PLIP interactions: 2 interactions with chain C Hydrogen bonds: C:N.1098, C:H.1101

1 x NAG- NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(5-4)-2-acetamido-2-deoxy-beta-D-glucopyranose

NAG-NAG-NAG.13: 3 residues within 4Å: Chain B: K.558 Chain C: N.280, N.282 No protein-ligand interaction detected (PLIP)

29 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)

NAG.17: 2 residues within 4Å: Chain A: N.280, N.282 Ligand excluded by PLIP NAG.18: 1 residues within 4Å: Chain A: N.657 Ligand excluded by PLIP NAG.19: 1 residues within 4Å: Chain A: N.616 Ligand excluded by PLIP NAG.20: 2 residues within 4Å: Chain A: N.709, G.1131 Ligand excluded by PLIP NAG.21: 3 residues within 4Å: Chain A: F.59, N.61, P.631 Ligand excluded by PLIP NAG.22: 2 residues within 4Å: Chain A: N.234 Chain C: H.519 Ligand excluded by PLIP NAG.23: 2 residues within 4Å: Chain A: N.603, T.604 Ligand excluded by PLIP NAG.24: 1 residues within 4Å: Chain A: N.165 Ligand excluded by PLIP NAG.25: 2 residues within 4Å: Chain A: F.342, N.343 Ligand excluded by PLIP NAG.26: 2 residues within 4Å: Chain A: N.1074, T.1076 Ligand excluded by PLIP NAG.27: 2 residues within 4Å: Chain B: N.280, N.282 Ligand excluded by PLIP NAG.28: 1 residues within 4Å: Chain B: N.657 Ligand excluded by PLIP NAG.29: 2 residues within 4Å: Chain B: N.616, T.618 Ligand excluded by PLIP NAG.30: 2 residues within 4Å: Chain B: N.709, I.1130 Ligand excluded by PLIP NAG.31: 3 residues within 4Å: Chain B: F.59, N.61, P.631 Ligand excluded by PLIP NAG.32: 1 residues within 4Å: Chain B: N.234 Ligand excluded by PLIP NAG.33: 2 residues within 4Å: Chain B: N.603, T.604 Ligand excluded by PLIP NAG.34: 1 residues within 4Å: Chain B: N.165 Ligand excluded by PLIP NAG.35: 2 residues within 4Å: Chain B: F.342, N.343 Ligand excluded by PLIP NAG.36: 3 residues within 4Å: Chain B: N.1074, F.1075, T.1076 Ligand excluded by PLIP NAG.37: 1 residues within 4Å: Chain C: N.657 Ligand excluded by PLIP NAG.38: 2 residues within 4Å: Chain C: N.616, T.618 Ligand excluded by PLIP NAG.39: 3 residues within 4Å: Chain A: D.796 Chain C: N.709, I.1130 Ligand excluded by PLIP NAG.40: 3 residues within 4Å: Chain C: F.59, N.61, P.631 Ligand excluded by PLIP NAG.41: 1 residues within 4Å: Chain C: N.234 Ligand excluded by PLIP NAG.42: 2 residues within 4Å: Chain C: N.603, T.604 Ligand excluded by PLIP NAG.43: 1 residues within 4Å: Chain C: N.165 Ligand excluded by PLIP NAG.44: 3 residues within 4Å: Chain C: F.338, F.342, N.343 Ligand excluded by PLIP NAG.45: 2 residues within 4Å: Chain C: K.1073, N.1074 Ligand excluded by PLIP

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Walter, J.D. et al., Biparatopic sybodies neutralize SARS-CoV-2 variants of concern and mitigate drug resistance. Embo Rep. (2022)

Release Date

2021-08-04

Peptides

Spike glycoprotein: ABC
sybody#15: DEF
sybody#68: GHI

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
B

B
C

C
E

D
A

E
D

F
H

G
W

H
Y

I
X

Spike glycoprotein

sybody#15

sybody#68

Related Entries With Identical Sequence